2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure
The ABC is pleased with the release of the recent 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure. The dissemination of guideline-based medical therapy is the hallmark of the modern approach to pharmacotherapy. Based on recent evidence, new agents are now available to effectively treat heart failure with reduced EF, a condition more common in African Americans, with disproportionate premature onset, mortality and re-hospitalizations.
The new treatments in the updated guidelines are valsartan/sacubitril, an angiotensin receptor-neprilysin inhibitor, and ivabradine, a sinoatrial node modulator. Angiotensin-converting enzyme (ACE) inhibitors, beta blockers, diuretics and angiotensin II receptor blockers are among previously recommended therapies for heart failure. To ensure effective treatment, there is a rapid need to develop knowledge on how to use new therapies in combination with existing drugs.
The development and availability of new drugs, devices and biologics often means more treatment options for the thousands of patients affected by cardiovascular disease each year. This requires collaboration at all levels and support for increasing diversity in clinical trials. ABC endorses FDA Commissioner Dr. Robert Califf's efforts to increase diversity in trials and the varied activities by FDA and other organizations advocating for greater inclusion, including more minority participation.
Barbara Hutchinson, MD, PhD, FACC
Felix O. Sogade, MD, FACC, FHRS
ABC Chairman of the Board